Cancer Therapy News and Research

RSS

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

News outlets offer a variety of stories about Medicare, including details of a new bidding process for medical equipment and the scheduled cut in physician reimbursement.

8 Nov 2010

NCRI launches first virtual biobank for prostate cancer research

The first virtual biobank dedicated to prostate cancer research has been launched today by the National Cancer Research Institute (NCRI). The UK Prostate Cancer Sample Collection Database will house details of around 10,000 biological samples taken from men in the UK with and without prostate cancer.

8 Nov 2010

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government's Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma's novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

8 Nov 2010

Scientists discover new way to create human blood from adult skin

In an important breakthrough, scientists at McMaster University have discovered how to make human blood from adult human skin. The discovery, published in the prestigious science journal Nature today, could mean that in the foreseeable future people needing blood for surgery, cancer treatment or treatment of other blood conditions like anemia will be able to have blood created from a patch of their own skin to provide transfusions.

7 Nov 2010

Picis introduces charge capture solution for oncology treatment centers

Picis today introduced LYNX I/Point, a charge capture solution designed specifically for hospital-owned infusion and oncology treatment centers - where therapies are very expensive and accurately charging for services can be challenging.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Jefferson professor named 'Physician of the Year' by CancerCare

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently named 'Physician of the Year' by CancerCare, a national nonprofit organization that provides free, professional support services to anyone affected by cancer: people with cancer, caregivers, children, loved ones, and the bereaved. Dr. Mitchell is being honored for her work in gastrointestinal malignancies.

4 Nov 2010

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

3 Nov 2010

AHRQ study finds prostate cancer mortality rate declines by 45%

According to the U.S. Agency for Healthcare Research and Quality (AHRQ), compared to men in 1999, American men in 2006 that were fighting prostate cancer were 45% less likely to die from the disease.

3 Nov 2010

Image Guided IMRT preserves sexual function in men after prostatectomy

Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

Elekta presented solutions for ultimate precision in cancer care at an Investor Meeting in conjunction with the 52nd annual American Society for Radiation Oncology (ASTRO) Meeting, in San Diego. Elekta also discussed the market drivers in established and emerging markets, and explained its strategy for sustainable profitable growth.

From Elekta 2 Nov 2010

PITs compounds induce cell death and limit tumor growth

A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Dr Sartori’s contentious alternative therapy: inquest date set

The Medical Practitioner's Board of Western Australia is looking into the case of a doctor and her role in an alternative cancer therapy program. Five cancer patients have died after apparently being given industrial solvents and dangerous minerals as a part of an alternative therapy program by Alexandra Boyd, a well-known Mosman Park breast cancer specialist. She along with two registered nurses administered the concoctions to the people in question.

1 Nov 2010

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer. The Company initiated in December 2009 a multi-center Phase I clinical trial of ensituximab (NPC-1C) for the treatment of advanced pancreatic and colorectal cancer.

1 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University of Texas Southwestern and Fox Chase Cancer Center, will be presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego from October 31 to November 4.

1 Nov 2010

Annual meeting of INFORMS to take place at Austin Convention Center

When 4,000 experts in everything from laws about using your cell phone while driving to using math to decide whether to punt or pass on fourth down come to Austin on November 7, the city will find itself deluged not only by smart people who use math for a living but also problem solvers who tackle America's greatest threats.

30 Oct 2010

Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentations at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place in San Diego from October 31-November 4.

30 Oct 2010

Cancer Therapy News and Research

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

NCRI launches first virtual biobank for prostate cancer research

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Scientists discover new way to create human blood from adult skin

Picis introduces charge capture solution for oncology treatment centers

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

Jefferson professor named 'Physician of the Year' by CancerCare

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

AHRQ study finds prostate cancer mortality rate declines by 45%

Image Guided IMRT preserves sexual function in men after prostatectomy

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

PITs compounds induce cell death and limit tumor growth

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

Dr Sartori’s contentious alternative therapy: inquest date set

Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Annual meeting of INFORMS to take place at Austin Convention Center

Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News